Justifying the Value of Personalized Medicine

Matthew C. Palmgren, PharmD

Video Categories: Value

Matthew Palmgren presents the key issues that help justify the value and cost of personalized medicines
September 2, 2015

Relapsed/Refractory Setting

Dixie-Lee Esseltine, MD and George Mulligan, PhD discuss the challenges in the current standards of care of patients with multiple myeloma in the relapse setting.

March 31, 2015

Ibrutinib and ABT199 for CLL

Jennifer R. Brown, MD, PhD, at Dana-Farber Cancer Institute in Boston, discusses what she believes are the most important items coming out of ASH for CLL this year. She mentions excellent study results being presented about the drugs ibrutinib and ABT199.